Sweden's Egetis Q2 revenue rises 23%
Sweden's Egetis Q2 revenue rises 23%
Overview
Sweden rare disease drug developer's Q2 revenue rose 23% at constant exchange rates
Company completed oversubscribed share issue raising MSEK 350 (about MUSD 38) gross
Egetis granted U.S. patent for MCT8 deficiency composition during quarter
Outlook
Egetis expects FDA review of Emcitate NDA to conclude by September 28, 2026
Company is accelerating preparatory launch activities for Emcitate in the U.S.
Egetis aims to optimize pricing and reimbursement and continue Emcitate launch in Europe
Result Drivers
EUROPEAN SALES GROWTH - Emcitate sales in Europe rose 23% at constant exchange rates, driven by continued launch activities and the conclusion of German price negotiations
Company press release: ID:nMFNbqVrcg
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
H1 Revenue |
| SEK 30.7 mln |
|
Q2 Revenue |
| SEK 17.4 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Egetis Therapeutics AB (publ) is SEK13.00, about 91.2% above its August 20 closing price of SEK6.80
The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 12 three months ago
Reuters Recommended Reads
Aug 20 - Sweden's Ascelia Pharma Q2 operating loss narrows
Aug 20 - Sweden's Medivir Q2 turnover falls
Aug 19 - US FDA approves Regeneron's rare bone disorder drug
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)